1. In postmenopausal patients with ulcerative colitis (UC) or Crohn’s disease (CD), approximately one-third had osteoporosis while approximately 40% had ...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients ...
1. Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in ...
1. The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed ...
1. Sarcopenia is associated with an increased risk of adverse postoperative outcomes in older adults with inflammatory bowel disease (IBD). ...
1. Management of pediatric ulcerative colitis with tofacitinib successfully induced corticosteroid-free remission in 16% of patients at week 8 following ...
1. In this retrospective study, it was found that inflammatory bowel disease (IBD) activity was associated with poorer sleep scores ...
1. In this randomized controlled trial, patients with ulcerative colitis taking mirikizumab had higher rates of clinical remission compared to ...
